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Cannabis, cancer and cycling may seemlike a rather strange combination, butit is a combination that provides the
foundation for a rather unique form of social
activism with ramifications for medical health. The
Medical Cannabis Bike Tour (MCBT) is a non-
profit organisation that has been raising money
for medical research into the potential of
cannabis as a treatment for cancer. Since the
bike tour began in 2012 it has taken its
message to a different part of Europe each year.
The 420km, three-day sportive has been to
Spain, Italy, Slovenia, Austria, Germany, Holland
and the Czech Republic, and the number of
riders increases every year.
The MCBT has become something of a rallying
call for medical cannabis, and over the past six
years its popularity has seen riders and support
team volunteers arriving from around the world to
get involved. Participants include cannabis users
and non-cannabis users. From its inception, the
distinctive racing yellow cycling tops have created
a visual impact for publicising the cause of
medical cannabis.
How did the Medical
Cannabis Bike Tour begin?
In 2012, medical cannabis was in its infancy.
North America’s cannabis industry was mostly
illegal and the picture in Europe was little different.
With little to offer investors with regard to a
controversial product, many excellent research
groups struggled to secure funding to test the
medical qualities of cannabis. Those frustrations
were also felt by people in the legal European
cannabis industry (those selling the means to
produce cannabis, from seeds to grow
equipment), who were following the available
research on cannabis and saw the contribution
the plant could make to medical science. 
As scientific and anecdotal articles about the
benefits of the plant proliferated on the internet,
the European legal cannabis sector witnessed
increasing numbers of people approaching them
with questions about medical cannabis. Patients
seeking alternative treatments contacted the
cannabis industry looking for help, and many were
people nearing the end of terminal illness.
It was from this environment that the Medical
Cannabis Bike Tour sprung. Two cannabis industry
insiders regularly followed the bulletins of the
research consortium the International Association
of Cannabinoid Medicines (IACM), which details
the latest international research and legal changes
on cannabis. The pioneering work of a team led
by Dr Manuel Guzman and Dr Guillermo Velasco
from Complutense University in Madrid, Spain,
stood out. 
Their research suggested that a combination of
cannabinoids and other anticancer agents can
eliminate GICs (glioma initiating cells) which fuel
brain tumours. The findings are significant as the
population of GICs impedes the effectiveness of
conventional brain cancer therapies. So, a
sponsored bike ride was organised to raise money
for this research programme.
This year, the bike tour’s fundraising efforts will
result in an independently funded clinical trial that
tests the effectiveness of the cannabinoids THC
and CBD (tetrahydrocannabinol and cannabidiol,
two of the active compounds found in cannabis)
as a first line therapy treatment, used in
combination with other anticancer drugs. The trial,
conducted on patients recently diagnosed with
glioblastoma, will take place in Spain and will be
overseen by the neuro-oncological research
organisation El Grupo Español de Investigaciónen
Neurooncología (GEINO).
Velasco, the research lead, says: “For the first
time, we will be using cannabinoids as a first line
therapy. For this reason, it’s very exciting. Having
the support of GEINO is really important. To have
such a serious organisation co-ordinating these
trials will give the study even more legitimacy.”
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Why cycling and cannabis? 
By using sport to raise awareness of medical
cannabis, the bike tour set out to challenge
negative stereotypes associated with the cannabis
plant which stood as an impediment to carrying
out medical cannabis research. 
“People have in their heads an idea of what
cannabis is,” explains Luc Krol, who owns
Amsterdam Paradise Seeds, seed bank, the
Nehterlands, and is the tour organiser. “When they
see the bike tour go past, they see cyclists. It’s
only when they look closer that they see the
mention of cannabis on the jerseys. Some of the
tour participants are cannabis users, others are
not, and many of us have been lifelong cyclists.
We hope to challenge preconceptions and change
the way people think about medical cannabis. 
“Since we began the tour, the use of medical
cannabis has become more widely accepted in
society at large across Europe. Once people get
over their preconceptions, once they see that it
can have a positive effect on the health of those
close to them, many of whom have no previous
association with cannabis, then attitudes
inevitably start to change. 
“Everywhere the bike tour goes, we are
welcomed. When they hear what we are doing
people are always supportive, and many have
been following the research about cannabis as a
potential cancer treatment.”
Overcoming obstacles 
As evidence grows on the utility of cannabis, the
legal path is structured by other legislation, and
significantly cannabis remains listed on the 1961
UN Single Convention on Narcotic Drugs. The
medicalisation of cannabis goes hand in hand with
extracting the component parts of cannabis for
various treatments. The World Health Organization
recently concluded that one such component, CBD,
“does not appear to have abuse potential or cause
harm” and so de-scheduled the extract, leaving
national legislators to determine legal status. 
Nationally, laws about medicines come into play
in a difficult exercise of categorisation. When the
UK regulator of medicines and healthcare
products, the MHRA, decided in 2016 that CBD
was a medicine that required licences in the
supply chain, they followed Article 1 of Council
Directive 2001/83/EEC included as Regulation 2
of the Human Medicines Regulations. 
For small to medium businesses, personal values
dominate business ethics. The majority of the
MCBT sponsorship comes from those operating
in the legal cannabis sector, so from the outside
the MBCT might look like opportunistic cannabis
traders trying to further their own profits by joining
the cancer bandwagon. Yet, the possibility that
cannabis, which has built their businesses, also
has the potential to cure certain cancers means
that there is a moral as well as economic
imperative driving most of the riders and
sponsors. Almost everyone on the MCBT has a
connection with cancer, through personal
experience with family or friends. 
The people involved with this ride are hard
working, taxpaying business people who share
with other business communities conservative
values of individual responsibility and collective
contribution. Nevertheless, they feel oppressed by
laws that restrict their businesses and criminalise
cannabis users.
Activism in action
On the ride, two subjects dominate evening
conversations: cycling and cannabis. The former
is about routes, hills, pain, elation and bikes; the
latter is about the quality of breeds and flavours,
medical research, and arrest and prison. The laws
on cannabis, which are often idiosyncratic, vary
greatly between European regions, countries,
towns and even parts of a town. While there
appears to be a movement towards greater
acceptance of medical cannabis, for those in the
business, that journey has been a flip-flop of
changing measures. 
Coming into contact with so many patients has also
changed them, exposing a moral crisis in the law
that has reignited activism. The oppression used to
be focused on their own cannabis culture, creating
a stigma that, over the years, some began to
absorb. But after seeing dying patients criminalised
for trying to use cannabis to survive, for many of
those involved, as well as the wider public, the
illegitimacy of the law became undeniable. Rights
to health conflated with rights to use cannabis.
After years of being made the pariah by
governments, people on the MCBT are fighting
back, not with angry protest but with a positive
contribution. The medicalisation of cannabis allows
the cannabis industry to give something back to
society on the key social value of health. The MCBT
follows a familiar model of sporting philanthropy
which, like so many other charity events, mixes
fundraising with visible sponsorship. However,
beneath these yellow jerseys is activism against
medical and social injustice.
The road ahead
For a while, the MCBT were pioneers, trying to
bring much-needed knowledge to the field of
medical cannabis research. As North American
legislation transforms the cannabis landscape,
corporate scale investment and business
practices may still muscle out the sort of
independent research where investment in
knowledge takes priority over investment in a
product. The MCBT was born out of the problem
of profit-driven research funding and the
organisers will be keeping a close eye on quality
medical cannabis research that needs funding.
This road trip is not over yet.
Tim Lay
Dr Jonathan Newman




Tim Lay is a freelance journalist who became
involved with the bike tour after losing both
parents to cancer. Dr Jonathan Newman is a
social anthropologist at the University of Sussex
who studies the cannabis industry.
SPECIAL FEATURE: MEDICAL CANNABIS
Reproduced by kind permission of Health Europa Quarterly, www.healtheuropa.eu © Health Europa 2018
